July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Anti-Inflammatory Action of a Novel Tetrapeptide in a Corneal Epithelial Cell Culture Model
Author Affiliations & Notes
  • Frank Gambino
    Microbiology & Immunology, Loyola University Chicago, Maywood, Illinois, United States
  • hui liu
    Opthamology, Loyola University Chicago, Maywood, Illinois, United States
    Refractive Surgery & Corneal Disease, Tianjin Medical University Eye Hospital, Tianjin, China
  • Cian Walsh
    Microbiology & Immunology, Loyola University Chicago, Maywood, Illinois, United States
  • Charles S Bouchard
    Opthamology, Loyola University Chicago, Maywood, Illinois, United States
  • Ping Bu
    Opthamology, Loyola University Chicago, Maywood, Illinois, United States
  • Bruce Ira Gaynes
    Opthamology, Loyola University Chicago, Maywood, Illinois, United States
    Co-Corresponding Author, Loyola University Chicago, Maywood, Illinois, United States
  • Liang Qiao
    Microbiology & Immunology, Loyola University Chicago, Maywood, Illinois, United States
    Co-Corresponding Author, Loyola University Chicago, Maywood, Illinois, United States
  • Footnotes
    Commercial Relationships   Frank Gambino, Shulov Innovative Science Ltd. (F); hui liu, None; Cian Walsh, None; Charles Bouchard, None; Ping Bu, None; Bruce Gaynes, Shulov Innovative Science Ltd. (F); Liang Qiao, Shulov Innovative Science Ltd. (F)
  • Footnotes
    Support   Richard A. Perritt Charitable Foundation, Illinois Society for the Prevention of Blindness (ISPB), Shulov Innovative Science Ltd. (SIS)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3823. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frank Gambino, hui liu, Cian Walsh, Charles S Bouchard, Ping Bu, Bruce Ira Gaynes, Liang Qiao; Anti-Inflammatory Action of a Novel Tetrapeptide in a Corneal Epithelial Cell Culture Model. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3823.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry Eye Disease (DED) is a disorder that affects over ten million worldwide. The pathogenesis of DED is not fully understood, however, inflammation at the ocular surface is a hallmark of the disease and its symptoms. Our purpose is to explore the anti-inflammatory effect of a novel synthetic tetrapeptide on experimental corneal inflammation in a cell culture model.

Methods : Human Corneal Epithelial Cells (HCECs) were treated with inflammasome inducers such as LPS, HNE, Nigericin, and others to model an inflammatory DED-state. Using a dosage response model, HCECs were pre-treated with a synthetic tetrapeptide followed by exposure to aforementioned suspected inflammatory DED inducers followed by measurement of IL-6 expression.

Results : Levels of pro-inflammatory cytokine IL-6 in HCECs pre-treated with our synthetic peptide followed by treatment with inflammatory agonists decreased from 52.45 ± 0.9121 pg/mL IL-6 with no pre-treatment of tetrapeptide to 38.08 ± 1.368 pg/mL IL-6 with pre-treatment of tetrapeptide (P<0.05) thereby approaching normative levels.

Conclusions : The novel synthetic tetrapeptide evaluated in this study appears useful in reducing levels of pro-inflammatory cytokines such as IL-6 to normative levels. These results provide a basis for a novel therapeutic drug in treating DED caused by putative inflammatory pathways.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×